Biogen Inc

Biogen's capital structure is characterized by a debt-to-equity ratio of 0.67, indicating a moderate reliance on debt financing. The company maintains a liquidity position with a current ratio of 1.83, suggesting it can cover its short-term obligations. However, its net cash position is negative after subtracting total debt, signaling potential liquidity risk. In terms of profitability, Biogen's return on equity (ROE) of 14.28% and return on assets (ROA) of 6.52% are strong, but these figures should be compared to the industry median to assess relative performance. The company's gross profit margin of 82.3% and operating margin of 25.9% are indicative of efficient cost management and pricing power. Geographically, Biogen's revenue is concentrated in North America, with a significant portion derived from the United States. The company's exposure to international markets is limited, which may affect its growth potential in emerging economies. Looking at growth, Biogen's revenue in the latest period was $10.98 billion. While the company has a history of stable revenue, the outlook for the current fiscal year suggests a modest growth trajectory. The capital expenditure of -$294.9 million indicates a reduction in investment, which may affect long-term growth. Biogen faces several risk factors, including the potential for dilution, which is currently assessed as low. The company's liquidity risk is medium, primarily due to its negative net cash position after debt. The risk assessment also highlights the importance of monitoring the company's debt levels and cash flow generation. Recent events, such as analyst estimates and price targets, suggest a generally positive outlook for Biogen. The mean price target of $217.97 and the median price target of $214.00 indicate that analysts expect the stock to appreciate. The mean recommendation of 2.30, with 7 strong-buy ratings, further supports this positive sentiment.